Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine

기사 요약

Merck reports Phase 2b/3 BRUNELLO trial data for remigromig in DME, achieving vision non-inferiority to ranibizumab alongside elevated adverse event rates.